Initial dosing of intermittent vancomycin in adults: estimation of dosing interval in relation to dose and renal function.
CKD-EPI
dosing nomogram
glomerular filtration
pharmacokinetics
therapeutic drug monitoring
vancomycin
Journal
European journal of hospital pharmacy : science and practice
ISSN: 2047-9956
Titre abrégé: Eur J Hosp Pharm
Pays: England
ID NLM: 101578294
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
received:
18
06
2019
revised:
24
07
2019
accepted:
30
07
2019
entrez:
24
8
2021
pubmed:
25
8
2021
medline:
2
4
2022
Statut:
ppublish
Résumé
Due to the high interindividual variability in vancomycin pharmacokinetics, optimisation of its dosing is still challenging. This study aimed to explore vancomycin pharmacokinetics in adult patients and to propose an easy applicable dosing nomogram for initial treatment. Vancomycin pharmacokinetics was calculated in a two-compartmental model based on therapeutic drug monitoring data. A linear regression model was used to explore the relationship between vancomycin elimination half-life and glomerular filtration rate estimated according the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula. In the whole study population (n=66), vancomycin volume of distribution, clearance and half-life median (IQR) values were 0.69 (0.58-0.87) L/kg, 0.031 (0.022-0.050) L/h/kg and 14.4 (9.5-25.2) hours, respectively. Vancomycin half-life was associated with glomerular filtration rate (r We propose an easy-to-use dosing nomogram for vancomycin therapy initiation that allows individualisation of the dosing interval with respect to the administered dose size and functional renal status.
Identifiants
pubmed: 34426481
pii: ejhpharm-2019-002013
doi: 10.1136/ejhpharm-2019-002013
pmc: PMC8403779
doi:
Substances chimiques
Anti-Bacterial Agents
0
Vancomycin
6Q205EH1VU
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
276-279Informations de copyright
© European Association of Hospital Pharmacists 2021. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Can J Hosp Pharm. 2012 May;65(3):180-7
pubmed: 22783028
PLoS One. 2013 Oct 18;8(10):e77169
pubmed: 24204764
Clin Pharmacokinet. 2004;43(13):925-42
pubmed: 15509186
Eur J Hosp Pharm. 2019 Mar;26(2):85-88
pubmed: 31157105
Pharmacotherapy. 2009 Nov;29(11):1275-9
pubmed: 19873687
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
Clin Infect Dis. 2006 Jan 1;42 Suppl 1:S5-12
pubmed: 16323120
Clin Pharmacokinet. 1986 Jul-Aug;11(4):257-82
pubmed: 3530582
Am J Ther. 2018 Sep/Oct;25(5):e602-e604
pubmed: 28650911
Infect Dis (Lond). 2017 Sep;49(9):674-679
pubmed: 28504034
Anaesth Intensive Care. 2014 Mar;42(2):178-84
pubmed: 24580382
J Infect Chemother. 2018 Apr;24(4):247-250
pubmed: 29195829
Intensive Care Med. 2013 Jul;39(7):1322-4
pubmed: 23604134